Opko Health, Inc. – ‘10KSB/A’ for 12/31/96

As of:  Tuesday, 5/6/97   ·   For:  12/31/96   ·   Accession #:  950116-97-870   ·   File #:  0-26078

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Amendment to Annual Report — Small Business   —   Form 10-KSB
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10KSB/A     Amendment to Annual Report -- Small Business           2     11K 
 2: EX-27       Financial Data Schedule                                1      6K 

10KSB/A   —   Amendment to Annual Report — Small Business

10KSB/A
1st Page of 2
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 FORM 10-KSB/A-1

[X]  ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES                  
EXCHANGE ACT OF 1934 (Fee Required)                                   

For the fiscal year ended December 31, 1996                           

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES              
EXCHANGE ACT OF 1934 (No Fee Required)                                

For the transition period from                 to                     
        ----------------

Commission File No. 0-26918                                           

 Cytoclonal Pharmaceutics Inc.
----------------------------------------------
(Name of small business issuer in its charter)

Delaware                                             75-2402409 
-------------------------------                           --------------------  
(State or other jurisdiction of                            (I.R.S. Employer     
incorporation or organization                             Identification No.)   

9000 Harry Hines Boulevard, Suite 330, Dallas, Texas             75235          
----------------------------------------------------           ----------       
(Address of principal executive offices)                       (Zip Code)       

Issuer's Telephone Number, including Area Code  (214) 353-2922                  
                              ----------------

Securities registered under Section 12(b) of the Exchange Act:                  

   Title of each class           Name of each exchange on which registered
   -------------------           -----------------------------------------
N/A                                      N/A          

Securities registered under Section 12(g) of the Exchange Act:                  

 Common Stock $.01 par value
 ---------------------------
(Title of Class)

Check whether the issuer: (1) filed all reports required to be filed by Section 
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter  
period that the registrant was required to file such reports), and (2) has been 
subject to such filing requirements for the past 90 days.  Yes   X   No         
                                                           -----   -----

10KSB/A
Last Page of 2
TOC
1st
Previous
Next
↓Bottom
Just 2nd
SIGNATURES

 In accordance with Section 13 or 15(d) of the Exchange Act, the
registrant caused this amended report to be signed on its behalf by the         
undersigned, thereunto duly authorized.                                         

                       CYTOCLONAL PHARMACEUTICS INC.

Dated: May 5, 1997                By: /s/ Arthur P. Bollon, Ph.D.               
                              ----------------------------
                                  Arthur P. Bollon, Ph.D., President

        In accordance with the Exchange Act, this report has been signed below
by the following on behalf of the registrant and in capacities and on the dates 
indicated.                                                                      

                                                                [Download Table]

Signature                      Capacity                        Date       
---------                      --------                        ----       
                                                                          
/s/ Arthur P. Bollon,          Chairman, President, Chief      May 5, 1997
-----------------------------  Executive Officer and Director             
                               (principal executive officer)              
Arthur P. Bollon, Ph.D                                                    

/s/ Ira Gelb, M.D.             Director                        May 5, 1997
-----------------------------                                             
Ira Gelb, M.D.                                                            

/s/ Irwin C. Gerson            Director                        May 5, 1997
-----------------------------                                             
Irwin C. Gerson                                                           

/s/ Walter M. Lovenberg        Director                        May 5, 1997
-----------------------------                                             
Walter M. Lovenberg, Ph.D.                                                

/s/ Daniel Shusterman          Vice President Operations,      May 5, 1997
-----------------------------  Treasurer and Chief Financial              
Daniel Shusterman, J.D.        Officer (principal financial               
                               and accounting officer)                    

38

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘10KSB/A’ Filing		Date		First		Last			Other Filings
Filed on:		5/6/97
		5/5/97		2
For Period End:		12/31/96		1					10KSB40
									List all Filings